^
    1d
    Systemic Therapy for Salivary Gland Cancers: A Review of Targeted and Chemotherapeutic Approaches. (PubMed, Curr Treat Options Oncol)
    Small-molecule tyrosine kinase inhibitors such as lenvatinib and axitinib may provide disease stabilization in adenoid cystic carcinoma, although tumor shrinkage is uncommon and toxicity limits their long-term use. For most patients without a targetable alteration, platinum-based combinations remain the pragmatic choice, though expectations for benefit should be tempered. Future strategies will likely hinge on optimizing biomarker-driven therapies, expanding access to antibody-drug conjugates, and pursuing collaborative trial designs to overcome the rarity and heterogeneity of these tumors.
    Review • Journal • IO biomarker
    |
    AR (Androgen receptor)
    |
    HER-2 positive • AR positive
    |
    Lenvima (lenvatinib) • axitinib
    3d
    A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers. (PubMed, ESMO Open)
    Our data support the clinical implementation of a tailored, histology-driven MP algorithm, potentially optimizing the genomic testing resources in SGCs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • AR (Androgen receptor) • HRAS (Harvey rat sarcoma viral oncogene homolog) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase) • MYBL1 (MYB Proto-Oncogene Like 1)
    |
    HER-2 positive • HER-2 negative
    4d
    Mucoepidermoid carcinoma of the thyroid gland: genetic insights and a rare clinical presentation. (PubMed, Virchows Arch)
    Co-existent PTC, immunopositivity for thyroid-differentiation markers, and the genetic profile confirm a squamoglandular metaplasia of follicular cells as the origin. The absence of MAML2 fusion questions its WHO categorization as a "salivary gland-type carcinoma." Detailed molecular profiling, while contributing to a better understanding of the pathogenesis of this enigmatic neoplasm, also helped decipher potentially actionable genetic variants.
    Journal
    |
    MME (Membrane Metalloendopeptidase) • KRT19 (Keratin 19) • TP63 (Tumor protein 63) • PAX8 (Paired box 8) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
    8d
    Unilocular cystic mucoepidermoid carcinoma: 6 cases reported and literature review. (PubMed, Int J Clin Exp Pathol)
    This case series aims to elucidate the clinicopathological and molecular characteristics of UCMEC to improve diagnostic accuracy. Accurate preoperative or intraoperative distinction from benign lesions and correct grading are paramount for determining the appropriate surgical scope and optimizing patient prognosis.
    Journal
    |
    TP63 (Tumor protein 63) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
    11d
    Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers (clinicaltrials.gov)
    P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 overexpression • HER-2 amplification
    |
    Trodelvy (sacituzumab govitecan-hziy)
    11d
    STARTRK-2: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (clinicaltrials.gov)
    P2, N=534, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date • Pan tumor
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    ALK rearrangement • ROS1 rearrangement
    |
    Xalkori (crizotinib) • Rozlytrek (entrectinib)
    12d
    GEMS-001: A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes (clinicaltrials.gov)
    P=N/A, N=114, Completed, University Health Network, Toronto | Active, not recruiting --> Completed
    Trial completion
    |
    Xpovio (selinexor)
    12d
    A case report of misdiagnosed adenoid cystic carcinoma of the parotid gland on ultrasound: imaging-pathological correlation and diagnostic implications. (PubMed, Gland Surg)
    This case highlights ACC's propensity for "benign-mimicking" sonographic features (well-defined margins, posterior enhancement, hypovascularity), contributing to misdiagnosis. It underscores that integrating elastography (for assessing stiffness), contrast-enhanced ultrasound (for evaluating washout patterns), CT/MRI (for detecting suspicious perineural spread), and molecular biomarkers (e.g., low Ki-67) is crucial to improving diagnostic accuracy and optimizing follow-up management for ACC.
    Journal
    |
    SOX10 (SRY-Box 10) • NFIB (Nuclear Factor I B) • TP63 (Tumor protein 63)
    18d
    Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers (clinicaltrials.gov)
    P1, N=30, Recruiting, Brigham and Women's Hospital | Not yet recruiting --> Recruiting | N=20 --> 30 | Trial completion date: Jan 2025 --> Nov 2031 | Trial primary completion date: Oct 2024 --> Mar 2031
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Venclexta (venetoclax) • cisplatin • carboplatin
    20d
    BTCRC-HN17-111: Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma (clinicaltrials.gov)
    P2, N=20, Recruiting, Manish Patel | Trial completion date: Oct 2025 --> Aug 2026 | Trial primary completion date: Sep 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    AR (Androgen receptor)
    |
    AR positive
    |
    Keytruda (pembrolizumab) • goserelin acetate